Postbiotics prepared by Lactobacillus plantarum CCFM1295 that upregulate the expression of HA synthase in skin cells

By using CCFM1295 and its epibiotics to upregulate the expression of HA synthase in skin cells, the problem of HA content reduction caused by skin aging is solved, significantly improving skin dryness and aging, and providing a safe and efficient skin care method.

CN116004469BActive Publication Date: 2024-11-05JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310065917.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-17
Publication Date
2024-11-05
Estimated Expiration
2043-01-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem of reducing HA content caused by skin aging, resulting in dry skin and wrinkles, and there are hidden dangers in the stability and safety of HA supplements.

Method used

Lactiplantibacillus planturum CCFM1295 and its prepared epibiotics were screened and used to upregulate the expression of HA synthetase with skin cells to promote HA synthesis in the skin.

Benefits of technology

It significantly upregulates the expression of HA synthetase in skin cells, enhances skin cell proliferation, improves skin dryness and aging problems, and has the effect of preventing and repairing skin dryness and aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116004469B_ABST
    Figure CN116004469B_ABST
Patent Text Reader

Abstract

The present invention discloses a postbiotic prepared by Lactobacillus plantarum CCFM1295 and having the function of up-regulating the expression of HA synthase in skin cells, and belongs to the fields of microbial technology and medical technology. The postbiotic prepared by Lactobacillus plantarum CCFM1295 of the present invention has the function of promoting the expression of HA synthase in the host, specifically including: (1) enhancing the proliferation of skin cells; (2) significantly up-regulating the expression of HAS1mRNA in skin cells; (3) significantly up-regulating the expression of HAS3mRNA in skin cells. The postbiotic prepared by Lactobacillus plantarum CCFM1295 of the present invention is used to prepare products for repairing dry skin and preventing skin aging, which has great application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a postbiotic prepared by Lactobacillus plantarum CCFM1295 and capable of up-regulating the expression of HA synthase in skin cells, belonging to the technical field of microorganisms. Background Art

[0002] HA synthase (HAS) is the most important enzyme for synthesizing HA. On the plasma membrane of mammals, HAS forms a long chain of HA by alternately connecting the two precursors of HA, UDP-GlcNAc and UDP-GlcA, with β-1,3 and β-1,4 glycosidic bonds. Finally, it leaves the cell membrane under the extrusion of the HAS enzyme and enters the extracellular or intracellular space to play a physiological regulatory role. There are three isozyme forms of HA synthase in mammals, namely HAS1, HAS2, and HAS3. HAS1 is expressed throughout the life process. Although the high molecular weight HA generated by catalysis is at a low level in various cells, it is essential for the normal physiological function of the body. HAS2 is significantly expressed in the embryonic development stage of mammals. The high molecular weight HA synthesized by it plays an important role in maintaining tissue structure and body fluid balance, and thus has great significance in the expansion and growth of body tissues. HAS3 is expressed in many tissues of late embryonic and adult mammals, can spontaneously act on the matrix around cells, and can bind to HA receptors on the cell surface to stimulate signal cascade reactions and produce a variety of physiological effects in cells.

[0003] HA, synthesized by HAS, is a common glycosaminoglycan in the human body, with the highest concentration in the skin. Due to the multiple hydroxyl groups in its structure, HA can form hydrogen bonds with water molecules, thus having a good water-retaining effect. It is the best moisturizing substance found in nature. The human skin also changes with the content and metabolism of HA during maturation and aging. When the HA content is rich, it can improve the skin's nutritional metabolism and keep the skin soft and smooth. As the skin ages, the HA content decreases, and the skin begins to become dry, lose elasticity, and wrinkles appear.

[0004] In order to solve the problem of reduced HA content, oral HA supplements or injection of HA fillers are generally used to maintain youthfulness. However, directly supplemented HA is easily degraded by hyaluronidase in the body. Chemical cross-linking is often used to increase its stability to delay the degradation of HA, which not only increases the application cost of HA, but also poses a safety hazard. Therefore, it is urgent to solve the loss of HA in the skin during aging and stably maintain the HA content of skin tissue through other means. At present, studies have reported that some lactic acid bacteria can achieve the effect of promoting skin health by using acetic acid, lactic acid, sphingomyelin and phospholipase produced by them, such as improving acne, resisting UV damage, promoting wound healing, and moisturizing. In addition, some bacterial extracts can increase the level of ceramide in the skin by upregulating the expression of ceramide synthase, thereby maintaining the integrity of the skin stratum corneum. Therefore, it is a feasible strategy to improve skin problems by screening postbiotics that can upregulate the expression of HA synthase to promote HA synthesis in the skin. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a new use of Lactobacillus plantarum and postbiotics prepared therefrom in up-regulating the expression of HA synthase in skin cells.

[0006] The present invention provides a strain of Lactobacillus planturum CCFM1295, which has been deposited in Guangdong Provincial Microbiological Culture Collection Center on November 13, 2022, with a deposit number of GDMCC No.62973, and a deposit address of Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0007] The colonies of Lactiplantibacillus planturum CCFM1295 on the MRS solid culture medium are round, white and smooth.

[0008] The Lactobacillus planturum CCFM1295 is a Gram-positive bacterium, facultative anaerobic, thermophilic, with an optimum growth temperature of 35-40° C. and an optimum growth pH of 6.0-7.0.

[0009] The invention provides a composition, which comprises the Lactobacillus plantarum CCFM1295.

[0010] In one embodiment, the composition contains the Lactobacillus plantarum CCFM1295 and / or the postbiotics prepared by the Lactobacillus plantarum CCFM1295.

[0011] In one embodiment, the composition is a postbiotic prepared by Lactobacillus plantarum CCFM1295.

[0012] In one embodiment, the postbiotics include dead cells, fermentation supernatant, bacterial lysate and / or fermentation broth.

[0013] In one embodiment, the method for preparing the postbiotics is to inoculate the above-mentioned Lactobacillus plantarum CCFM1295 into a fermentation medium to obtain a bacterial liquid, and perform heat treatment to obtain a fermentation liquid.

[0014] In one embodiment, the heat treatment is performed at 60-70° C. for 25-35 min.

[0015] In one embodiment, the method for preparing the bacterial lysate is to perform high-pressure homogenization on the fermentation broth prepared above, centrifuge to obtain the bacterial lysate, and dry it to obtain the postbiotic powder or directly use it as the postbiotic.

[0016] In one embodiment, the dead cells are inactivated bacterial cells obtained by heat treatment or freeze-drying the bacterial sludge precipitate obtained by centrifuging the fermentation broth.

[0017] In one embodiment, the fermentation supernatant is the supernatant obtained by centrifuging the fermentation broth.

[0018] In one embodiment, the postbiotics can be dried into powder or used directly by various drying methods such as vacuum drying, spray drying, vacuum freeze drying, fluidized bed drying, etc.

[0019] The present invention also provides application of the Lactobacillus plantarum CCFM1295 or the composition in promoting skin cell proliferation.

[0020] In one embodiment, the application is to treat skin cells with the postbiotics prepared by Lactobacillus plantarum CCFM1295.

[0021] In one embodiment, the skin cells are human keratinocytes.

[0022] In one embodiment, the postbiotic contains ≥1.0×10 7 CFU / ml concentration of bacterial components.

[0023] The present invention provides application of the Lactobacillus plantarum CCFM1295 or the composition in up-regulating the expression of HA synthase in skin cells.

[0024] In one embodiment, the application is to co-culture the postbiotics prepared by Lactobacillus plantarum CCFM1295 with skin cells for a period of time.

[0025] In one embodiment, the skin cells are human keratinocytes.

[0026] In one embodiment, the culture time is 4 hours.

[0027] In one embodiment, the HA synthetase comprises three isozymes, namely HAS1, HAS2, and HAS3.

[0028] The present invention provides the use of the above composition in up-regulating the expression of HA synthase in skin cells and in preparing a drug for preventing and / or repairing related symptoms such as dry skin and aging.

[0029] In one embodiment, the HA synthetase includes HAS1, HAS2, and HAS3.

[0030] In one embodiment, the symptoms associated with dry skin include skin becoming less elastic, rough, and having fine lines.

[0031] In one embodiment, the symptoms associated with skin aging include increased sensitivity of the skin to temperature, sagging, irregular pigmentation, significantly increased wrinkles, decreased skin resistance, etc.

[0032] The present invention provides products containing the plant lactobacillus CCFM1295 or the postbiotics, and the products include food, cosmetics, skin care products, and external medicines.

[0033] In one embodiment, the cosmetic comprises the above composition, matrix raw materials and / or conventional auxiliary materials.

[0034] In one embodiment, the matrix raw materials include oil raw materials, wax raw materials, synthetic oil raw materials, powdery raw materials, colloid raw materials, coagulants, and surfactants.

[0035] In one embodiment, the conventional auxiliary materials include one or more of moisturizers, whitening agents, flavoring agents, adhesives, lubricants, preservatives, film agents, antioxidants, emulsifiers, and cosmetic nutritional additives.

[0036] In one embodiment, the skin care product comprises the above composition, basic raw materials and / or conventional auxiliary materials.

[0037] In one embodiment, the basic raw materials include hydrocarbons, waxes, and oil raw materials.

[0038] In one embodiment, the hydrocarbons include liquid paraffin, solid paraffin, microcrystalline paraffin, ozokerite, and vaseline.

[0039] In one embodiment, the waxes include palm wax, candelilla wax, jojoba wax, wood wax, lanolin, and beeswax.

[0040] In one embodiment, the oil raw material includes olive oil, coconut oil, castor oil, cottonseed oil, rice bran oil, and tea seed oil.

[0041] In one embodiment, the conventional excipients include solvents, emollients, penetrants, stabilizers, chelating agents, thickeners, and dispersants.

[0042] In one embodiment, the drug comprises a composition, a pharmaceutical carrier and / or a pharmaceutical excipient.

[0043] In one embodiment, the drug carrier comprises microcapsules, microspheres, nanoparticles and liposomes.

[0044] In one embodiment, the pharmaceutical excipient comprises an excipient and an additive.

[0045] In one embodiment, the pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.

[0046] In one embodiment, the additional agent comprises microcrystalline cellulose, hydroxypropyl methylcellulose and refined lecithin.

[0047] In one embodiment, the dosage form of the drug comprises capsules, granules, mixtures, tablets or tinctures.

[0048] Beneficial effects:

[0049] The present invention screened and obtained a strain of Lactiplantibacillus planturum CCFM1295. The postbiotics prepared by the strain of Lactiplantibacillus planturum CCFM1295 have the effect of repairing skin dryness, aging and other related symptoms, which is specifically embodied in:

[0050] (1) Enhance skin cell proliferation;

[0051] (2) Significantly up-regulated HAS1 mRNA expression;

[0052] (3) Significantly up-regulated HAS3 mRNA expression;

[0053] Therefore, the postbiotics prepared by Lactiplantibacillus planturum CCFM1295 have great application prospects in the preparation of drugs for preventing and / or repairing dry skin and aging, and even preventing and / or alleviating skin problems related to aging and metabolic disorders.

[0054] Biomaterial Deposit

[0055] A strain of Lactiplantibacillus planturum CCFM1295, taxonomically named Lactiplantibacillus planturum, was deposited in the Guangdong Provincial Microbiological Culture Collection Center on November 13, 2022, with the collection number GDMCC No.62973, and the collection address is Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 : Effects of postbiotics prepared by Lactobacillus plantarum CCFM1295 on skin cell proliferation.

[0057] Figure 2 :Effects of different postbiotics on the expression of HAS1 mRNA in skin cells.

[0058] Figure 3 :Effects of different postbiotics on the expression of HAS3 mRNA in skin cells.

[0059] “*” indicates statistical difference compared with the Model group (P<0.05), “**” indicates significant statistical difference compared with the Model group (P<0.01), and “***” indicates extremely significant statistical difference compared with the Model group (P<0.001). DETAILED DESCRIPTION

[0060] The present invention will be further described below in conjunction with specific embodiments.

[0061] The skin cells involved in the following examples were purchased from Shanghai Cell Bank. Lactobacillus paracasei FXJWS3M2 and Lactobacillus plantarum 23 were from self-screened strains in the Food Biology Center Laboratory of Jiangnan University.

[0062] The culture medium involved in the following examples is as follows:

[0063] MRS liquid culture medium: yeast powder 5.0 g / L, beef extract 10.0 g / L, peptone 10.0 g / L, glucose 20.0 g / L, anhydrous sodium acetate 2.0 g / L, diammonium hydrogen citrate 2.0 g / L, dipotassium hydrogen phosphate 2.6 g / L, manganese sulfate monohydrate 0.25 g / L, magnesium sulfate heptahydrate 0.5 g / L and Tween-80 1 mL / L, pH 6.2-6.4.

[0064] MRS solid culture medium: yeast powder 5.0 g / L, beef extract 10.0 g / L, peptone 10.0 g / L, glucose 20.0 g / L, anhydrous sodium acetate 2.0 g / L, diammonium hydrogen citrate 2.0 g / L, dipotassium hydrogen phosphate 2.6 g / L, manganese sulfate monohydrate 0.25 g / L, magnesium sulfate heptahydrate 0.5 g / L, Tween-80 1 mL / L and agar 20.0 g / L, pH 6.2-6.4.

[0065] Cell culture medium: 89% (v / v) DMEM medium + 10% v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin solution (the content of penicillin in the mixed solution is 10000 U / mL, and the concentration of streptomycin is 10 mg / mL).

[0066] Example 1: Screening and identification of Lactobacillus plantarum

[0067] 1. Screening

[0068] The sample comes from healthy human feces. After pretreatment, the sample is stored in a -80°C refrigerator in 30% glycerol. After being taken out and thawed, it is mixed and 0.5 mL of the sample is pipetted and added to 4.5 mL of normal saline, and gradient dilution is performed with 9 g / L normal saline. The appropriate gradient dilution liquid is selected and spread on MRS solid culture medium, and cultured at 37°C for 48 hours. The typical colony of Lactobacillus plantarum is picked and streaked on MRS solid culture medium for purification, and a single colony is picked and transferred to MRS liquid culture medium for bacterial enrichment, and preserved in 30% glycerol to obtain Lactobacillus plantarum CCFM1295; among them, the typical colony of Lactobacillus plantarum is round, milky white, and smooth and convex.

[0069] 2. Identification

[0070] The genome of strain CCFM1295 was extracted, and the 16S rDNA of strain CCFM1295 was amplified and sequenced (by Suzhou Jinweizhi Biotechnology Co., Ltd., and the nucleotide sequence amplified from the 16S rDNA of CCFM1295 was compared with the nucleic acid sequence in NCBI, and the results showed that the strain was Lactobacillus plantarum, and was named Lactobacillus planturum CCFM1295.

[0071] Example 2: Cell recovery and culture

[0072] First, take out the frozen immortalized human keratinocytes (HaCaT), quickly thaw them in a 37°C water bath, then centrifuge at 1000r / min for 3min, discard the supernatant, add an appropriate volume of cell culture medium to resuspend the cells, place them in a culture dish, and culture them in a 37°C incubator containing 5% CO2. When the cells grow to 70% to 80% fusion, cell passage is performed.

[0073] Example 3: Preparation of postbiotics by Lactobacillus plantarum CCFM1295

[0074] The solid MRS culture medium was cultured in a water-insulated constant temperature incubator at 37°C for 24-48 hours to obtain a single colony; the single colony was picked and inoculated into an MRS liquid culture medium, and cultured at 37°C for 12-18 hours to obtain a culture solution 1; the culture solution 1 was inoculated into an MRS liquid culture medium at an inoculation rate of 2% (v / v), and cultured at 37°C for 12 hours to obtain a seed solution; the seed solution was inoculated into an MRS liquid culture medium at a rate of 3-5% (v / v) for expansion culture, and cultured at a temperature of 37°C for 18-24 hours to obtain a concentration of 1.06×10 10 CFU / ml bacterial solution.

[0075] The bacterial solution was heat treated at 65°C for 30 min, and then homogenized in a high-pressure homogenizer (800-1200 MPa, 3 times) to obtain a bacterial lysate, and the bacterial lysate was freeze-dried to obtain postbiotic freeze-dried powder for later use.

[0076] Example 4: Effect of postbiotics prepared by Lactobacillus plantarum CCFM1295 on HaCaT cell proliferation

[0077] The postbiotics of Lactobacillus plantarum CCFM1295 were prepared according to the method of Example 3.

[0078] Take 100 μl of HaCaT cells in the logarithmic growth phase and add 5×10 5 The cells were seeded at a concentration of 10 cells / well in a 96-well plate, with the outermost circle filled with PBS solution to prevent edge effect. After culturing for 24 hours to allow them to adhere to the wall, blank group, control group, and treatment group were set up.

[0079] Blank group: containing only cell culture medium without HaCaT cells;

[0080] Control group: contained both cell culture medium and HaCaT cells without postbiotics;

[0081] Treatment group: The postbiotics were resuspended in cell culture medium (the amount of postbiotics after resuspension was the same as that of fermentation to 1.0×10 7CFU / ml of bacterial liquid was used to prepare the postbiotics, and 100 μl of Lactobacillus plantarum CCFM1295 postbiotics, Lactobacillus paracasei FXJWS3M2 postbiotics or Lactobacillus plantarum 23 postbiotics were added respectively, and incubated in an incubator at 37°C for 4 hours. After the incubation, 10 μl of CCK8 solution was added to each well and incubated for 2 hours to measure the absorbance value (OD) at 450nm. Each group had 6 replicate wells, and the experiment was repeated 3 times. The cell proliferation rate was calculated according to the following formula: Cell proliferation rate (%) = (OD value of treatment group - OD value of blank group) / (OD value of control group - OD value of blank group) × 100%.

[0082] Depend on Figure 1 It can be seen that the cell proliferation rate of the control group was 99%, and the cell proliferation rates of the postbiotics prepared by adding Lactobacillus plantarum CCFM1295, Lactobacillus paracasei FXJWS3M2 and Lactobacillus plantarum 23 were 123%, 116% and 108%, respectively. The results show that the content of 1.0×10 7 CFU / ml of inactivated bacterial postbiotics promoted the proliferation of skin cells.

[0083] Example 5: Effect of postbiotics prepared by Lactobacillus plantarum CCFM1295 on HAS1 mRNA and HAS3 mRNA in HaCaT cells

[0084] The preparation methods of Lactobacillus plantarum CCFM1295 postbiotics, Lactobacillus paracasei FXJWS3M2 postbiotics and Lactobacillus plantarum 23 postbiotics are the same as those in Example 3.

[0085] HaCaT cells were cultured at 2.5 × 10 6 The cells were inoculated with 100 μg / ml on a 12-well plate and cultured overnight until the cells adhered to the wall. The old culture medium was discarded and the cells were rinsed with PBS three times. The control group and the treatment group were set up.

[0086] Control group: no postbiotics added;

[0087] Treatment group: resuspend the postbiotics in cell culture medium (the amount of postbiotics after resuspending is the same as that of fermentation to 1.0×10 7 CFU / ml of bacterial liquid), 2 ml of Lactobacillus plantarum CCFM1295 postbiotics, Lactobacillus paracasei FXJWS3M2 postbiotics or Lactobacillus plantarum 23 postbiotics were respectively aspirated and cultured in an incubator at 37°C for 4 h, with three replicates for each sample.

[0088] After the culture was completed, the culture supernatant was discarded, each well was quickly washed 3 times with PBS, 1 ml of cell lysis solution was added to each well, and the cells were repeatedly blown and the cell lysis solution was aspirated to extract RNA, which was reverse transcribed into cDNA using an RT-PCR reverse transcription kit. The expression of genes in HaCaT cells was detected by real-time fluorescence quantitative method, and 2-△△Ct The expression levels of HAS1 mRNA and HAS3 mRNA were calculated using the formula, where the internal reference was GAPDH and the primers were described in Table 1

[0089] Table 1 Primers and sequences

[0090] Oligo Name Primer sequences describe F-qPCR-hHAS1 GAGCCTCTTCGCGTACCTG Hyaluronan synthase 1 (HAS1) R-qPCR-hHAS1 CCTCCTGGTAGGCGGAGAT Hyaluronan synthase 1 (HAS1) F-qPCR-hHAS3 GAGATGTCCAGATCCTCAACAA Hyaluronan synthase 3 (HAS3) R-qPCR-hHAS3 CCCACTAATACACTGCACAC Hyaluronan synthase 3 (HAS3)

[0091] Depend on Figure 2 , 3 It can be seen that, with the expression levels of HAS1 mRNA and HAS3 mRNA in the control group being 1, the expression levels of HAS1 mRNA of the postbiotics prepared by Lactobacillus plantarum CCFM1295, Lactobacillus paracasei FXJWS3M2, and Lactobacillus plantarum 23 were 1.98, 0.33, and 0.91, respectively; the expression levels of HAS3 mRNA were 4.18, 0.74, and 1.24, respectively. Compared with other postbiotics, the postbiotic group prepared by Lactobacillus plantarum CCFM1295 significantly promoted the expression of HAS1 mRNA (nearly 1 times that of the control group) and the expression of HAS3 mRNA (more than 3 times that of the control group).

[0092] The results of cell experiments showed that the postbiotic group prepared by Lactobacillus plantarum CCFM1295 has the ability to upregulate the expression of HA synthase.

[0093] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. Lactobacillus plantarum Lactiplantibacillus plantarum )CCFM1295 was deposited in Guangdong Provincial Microbiological Culture Collection Center on November 13, 2022, with the deposit number GDMCC No.62973.

2. A composition, characterized in that Containing the Lactobacillus plantarum CCFM1295 of claim 1 and / or a postbiotic containing the Lactobacillus plantarum CCFM1295 of claim 1.

3. The composition according to claim 2, characterized in that The postbiotics are dead cells and / or bacterial lysates of Lactobacillus plantarum CCFM1295.

4. A method for preparing a postbiotic of Lactobacillus plantarum CCFM1295, characterized in that: The plant lactobacillus CCFM1295 described in claim 1 is inoculated into a fermentation medium to obtain a bacterial liquid, and the bacterial liquid is subjected to heat treatment and high-pressure homogenization to obtain postbiotics.

5. The method according to claim 4, characterized in that The heat treatment is carried out at 60-70° C. for 25-35 min.

6. Postbiotics prepared by the method of claim 4 or 5.

7. Food containing the Lactobacillus plantarum CCFM1295 of claim 1 or the postbiotics of claim 6.

8. A health product containing the Lactobacillus plantarum CCFM1295 of claim 1 or the postbiotics of claim 6.

9. A medicine containing the Lactobacillus plantarum CCFM1295 of claim 1 or the postbiotic of claim 6.